Blue-Zone’s story begins in Toronto, Canada in the year 1996. The company’s founder, Ms. Dusanka Filipovic, P. Eng., acquired the global commercialization rights for the Deltasorb® Technology and launched Blue-Zone Technologies Ltd., the world’s first cleantech pharma company.
Since March 2024 Blue-Zone has been led by it’s CEO, Michael Logerfo, who has over 20 years of experience meeting the product requirements of patients in critical care institutions around the world, most recently as COO of Piramal Critical Care.
Blue-Zone’s team includes a talented group of professionals with a range of key capabilities, but most importantly they share a passion for our planet and are dedicated to finding economical and efficient solutions to reduce greenhouse gas emissions and establish a sustainable source of anesthetic gases to serve patients and their healthcare providers.
Is to reduce healthcare facility hazardous environmental waste in a cost-effective manner by applying BZ patented technology. We collect waste anesthetic gas normally vented into the environment and process the collected material into its pure form, providing a sustainable, cost-effective source of inhalation anesthetics.
Our Core Values define us as an organization. We pride ourselves on manifesting these values with every interaction.
We commit and deliver on our commitments.
We are honest and consistent in all that we do.
We leverage our respective strengths to achieve more together than we could alone.
We care for each other and our communities.
Michael brings a wealth of experience as a seasoned pharmaceutical executive and a recognized leader in the anesthesia space. As the former President and COO of Piramal Critical Care Inc., Michael played a pivotal role in transforming the organization and driving significant growth of the company.
Sean Karamchandan is an accomplished investor and healthcare entrepreneur. As an investor Sean has deep experience working with global leaders in healthcare service, hospital operations, pharmaceuticals, healthcare policy and biotechnology. As an entrepreneur, Sean founded, developed and commercialized a company focused on insulin digital injection delivery systems, which he sold in 2011. Sean earned an AB in Economics from Harvard University and an MBA from Columbia’s Graduate School of Business.
Thomas Stanley is a seasoned R&D professional with experience in plastics, silicones, and water treatment industries. Tom’s career has spanned over 32 years and includes positions at General Electric and Suez Water Technologies and Solutions. Tom holds advanced degrees in Chemical Engineering including a PhD from U of Pennsylvania.
Martin Marino has over 30 years of experience in corporate legal roles and executive management functions in the pharmaceutical industry, having previously served as Global General Counsel for the Merck Generics Group and VP of International Corporate Development for Apotex. He currently serves as Chairman of the Board for Microbix Biosystems Inc.
